Literature DB >> 19151365

Rapamycin reduces seizure frequency in tuberous sclerosis complex.

Jennifer Muncy1, Ian J Butler, Mary Kay Koenig.   

Abstract

The authors present a 10-year-old girl with tuberous sclerosis complex who has been receiving rapamycin for 10 months for seizure control. She was started at 0.05 mg/kg/d and titrated to an effective dose of 0.15 mg/kg/d. There was a dramatic reduction in seizure frequency with rapamycin therapy. Further studies are needed to objectively investigate the benefits of rapamycin in tuberous sclerosis complex and to clarify its mechanism of seizure control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151365      PMCID: PMC3072696          DOI: 10.1177/0883073808324535

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  1 in total

1.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Lin Xu; David H Gutmann; Michael Wong
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

  1 in total
  45 in total

Review 1.  Is epilepsy a preventable disorder? New evidence from animal models.

Authors:  Kathryn A Giblin; Hal Blumenfeld
Journal:  Neuroscientist       Date:  2010-06       Impact factor: 7.519

Review 2.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

Review 3.  Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.

Authors:  Michael Wong
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

4.  A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

Authors:  Emmanuel Raffo; Antonietta Coppola; Tomonori Ono; Stephen W Briggs; Aristea S Galanopoulou
Journal:  Neurobiol Dis       Date:  2011-04-12       Impact factor: 5.996

Review 5.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

Review 6.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

7.  Before epilepsy unfolds: finding the epileptogenesis switch.

Authors:  Annamaria Vezzani
Journal:  Nat Med       Date:  2012-11       Impact factor: 53.440

Review 8.  Hippocampal granule cell pathology in epilepsy - a possible structural basis for comorbidities of epilepsy?

Authors:  Michael S Hester; Steve C Danzer
Journal:  Epilepsy Behav       Date:  2014-01-24       Impact factor: 2.937

9.  Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder.

Authors:  Whitney E Parker; Ksenia A Orlova; William H Parker; Jacqueline F Birnbaum; Vera P Krymskaya; Dmitry A Goncharov; Marianna Baybis; Jelte Helfferich; Kei Okochi; Kevin A Strauss; Peter B Crino
Journal:  Sci Transl Med       Date:  2013-04-24       Impact factor: 17.956

10.  Autism and mental retardation with convulsion in tuberous sclerosis: a case report.

Authors:  Asok Kumar Datta; Syamali Mandal; Suvo Bhattacharya
Journal:  Cases J       Date:  2009-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.